Search research articles
Contact Us
Filters
Showing results (81-90 of 116) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2006
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
Qi Liu, Luis Fayad, Fernando Cabanillas, et al.
British Journal of Haematology
|
January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Nam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Cancer
|
August 28, 2003
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
Bouthaina S Dabaja, Peter McLaughlin, Chul S Ha, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
British Journal of Haematology
|
July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Jason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
British Journal of Haematology
|
July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
Felipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
John F Seymour, Barbara Pro, Lillian M Fuller, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
Sven de Vos, André Goy, Shaker R Dakhil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
Nam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 116) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2006
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
Qi Liu, Luis Fayad, Fernando Cabanillas, et al.
British Journal of Haematology
|
January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Nam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Cancer
|
August 28, 2003
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
Bouthaina S Dabaja, Peter McLaughlin, Chul S Ha, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
British Journal of Haematology
|
July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Jason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
British Journal of Haematology
|
July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
Felipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
John F Seymour, Barbara Pro, Lillian M Fuller, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
Sven de Vos, André Goy, Shaker R Dakhil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
Nam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Page
of 12